Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
15.79 USD +1.74% Intraday chart for Day One Biopharmaceuticals, Inc. +7.63% +8.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Day One Biopharmaceuticals, Inc. Announces Executive Changes CI
Day One Biopharmaceuticals, Inc. Announces Board Appointments CI
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Day One Biopharmaceuticals' New Drug Application for Tovorafenib Granted Priority Review by FDA MT
Day One Biopharmaceuticals Shares Rally on FDA Priority Review DJ
Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor DJ
Day One Biopharmaceuticals, Inc. Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma CI
Day One Biopharmaceuticals Files Mixed Shelf MT
Sector Update: Health Care Stocks Higher Monday Afternoon MT
Day One Completes Rolling Submission of New Drug Application for Pediatric Brain Tumor Drug MT
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling Nda Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma CI
Day One Biopharmaceuticals, Sprint Bioscience Sign Exclusive License, Research Deal MT
Goldman Sachs Lowers Price Target on Day One Biopharmaceuticals to $54 From $63, Maintains Buy Rating MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Day One Biopharmaceuticals, Inc.(NasdaqGS:DAWN) added to Russell Microcap Growth Index CI
Chart Day One Biopharmaceuticals, Inc.
More charts
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The Company seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. It has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
15.79 USD
Average target price
35 USD
Spread / Average Target
+121.66%
Consensus
  1. Stock
  2. Equities
  3. Stock Day One Biopharmaceuticals, Inc. - Nasdaq
  4. News Day One Biopharmaceuticals, Inc.
  5. Day One Signs Cooperative Research, Development Deal With National Cancer Institute For Tovorafenib's Expanded Development